key: cord-0825177-1dodpq18 authors: Cervantes-Alvarez, E.; Limon-de la Rosa, N.; Salgado-de la Mora, M.; Valdez-Sandoval, P.; Palacios-Jimenez, M.; Rodriguez-Alvarez, F.; Vera-Maldonado, B. I.; Aguirre-Aguilar, E.; Escobar-Valderrama, J. M.; Alanis-Mendizabal, J.; Mendez-Guerrero, O.; Tejeda-Dominguez, F.; Torres-Ruiz, J.; Gomez-Martin, D.; Colborn, K. L.; Kershenobich, D.; Huang, C. A.; Navarro-Alvarez, N. title: Galectin-3 as a potential prognostic biomarker of severe COVID-19 in SARS-CoV-2 infected patients date: 2021-02-09 journal: nan DOI: 10.1101/2021.02.07.21251281 sha: 508cca6b70d46db44169f66b9d237ee0dd12c9f3 doc_id: 825177 cord_uid: 1dodpq18 BACKGROUND: Prognostic biomarkers are needed to identify patients at high-risk for severe COVID-19. Galectin-3 is known to drive neutrophil infiltration and release of pro-inflammatory cytokines contributing to airway inflammation. METHODS: In this prospective cohort, we assessed galectin-3 levels in 156 hospitalized patients with confirmed COVID-19. COVID-19 patients were diagnosed as either critical (>50% lung damage) or moderate (<50% of lung damage) based on computerized tomography. Patients who required invasive mechanical ventilation (IMV) and/or died during hospitalization were categorized as having a severe outcome, and non-severe outcome if they were discharged and none of the former occurred. RESULTS: Elevated serum galectin-3 was significantly higher in critical patients compared to moderate ones (35.91 {+/-} 19.37 ng/mL vs. 25 {+/-} 14.85 ng/mL, p<0.0001). Patients who progressed to a severe outcome including IMV and/or in-hospital death, presented higher galectin-3 levels (41.17 ng/mL [IQR 29.71 - 52.25] vs. 23.76 ng/mL [IQR 15.78 - 33.97] compared to those of a non-severe outcome, p<0.0001). Galectin-3 discriminated well between those with severe and non-severe outcome, with an AUC of 0.75 (95% CI 0.67 - 0.84, p<0.0001)and was found to be an independent predictor of severe outcome regardless of the percentage of lung involvement. Additionally, the combination of galectin-3, CRP and albumin, significantly improved its individual predicting ability with an AUC 0.84 (95% CI 0.77 - 0.91, p<0.0001). CONCLUSION: Circulating galectin-3 levels can be used to predict severe outcomes in COVID-19 patients, including the requirement of mechanical ventilation and/or death, regardless of the initial severity of the disease. Coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has afflicted tens of millions of people in a worldwide pandemic, straining health care systems across the world (1, 2) . Prognostic biomarkers that can identify high-risk patients are needed to improve clinical management and allow appropriate allocation of healthcare resources. Moreover, the lack of current curative therapies emphasizes the need to get a better understanding of the pathophysiological process behind SARS-CoV-2 infection and its long-term consequences for the development of targeted therapeutic strategies. Severe COVID-19 is associated with a systemic hyperinflammatory response characterized by high levels of circulating cytokines and chemokines (3) and substantial lung infiltration of innate immune cells (4) that can lead to acute respiratory distress syndrome (ARDS), multi-organ failure and death (5, 6) . Among the inflammatory cytokines are those associated with the activation of monocyte/macrophages such as Interleukin 6 (IL-6), Tumor necrosis factor (TNF), and the CC-chemokine ligand 2 (CCL2) (3, 6, 7) . Studies have shown that those inflammatory cytokines contribute to the recruitment of additional inflammatory cells that not only aggravate the lung damage, but also lead to pulmonary fibrosis (8, 9) . Subsets of M2 macrophages expressing profibrogenic genes have been found in the bronchoalveolar lavage of COVID-19 patients (4) , reflecting that the pathological process of SARS-CoV-2 infection not only involves an acute inflammatory response in the lungs, but is also associated with fibrotic complications (10) . Galectin-3 is a 29-35 kDa ß-galactoside binding lectin first identified in macrophages (11) . It plays an important role as a driver and amplifier of the pro-inflammatory response by promoting the release of several cytokines including IL-6 and TNF-α (12) , which are some of the major cytokines present in severe COVID-19 patients (3) . High levels of galectin-3 are known to drive neutrophil infiltration and the release of pro-inflammatory cytokines, contributing to acute airway inflammation (13) (14) (15) . In addition, studies have shown that endogenous galectin-3 can enhance the effects of viral infection by promoting host inflammatory responses (16, 17) . Galectin-3 is increasingly recognized as a potentially important diagnostic or prognostic biomarker for a variety of inflammatory and fibrotic diseases (18, 19) , (20) . Galectin-3 has been implicated in the development of organ fibrosis and is found to be highly upregulated in the injured lung, particularly in patients with idiopathic pulmonary fibrosis (21, 22) . Elevated circulating galectin-3 levels were previously reported to be associated with disease severity and mortality in ARDS patients (23) . Inflammation and fibrosis are key contributing mechanisms to the progression of severe COVID-19 and the development of its long-term consequences (3), (10, 24) . Given the known proinflammatory and profibrotic roles of galectin-3, we measured circulating galectin-3 levels in COVID-19 patients to assess its prognostic value. In this prospective study we followed 156 patients with confirmed COVID-19 from admission to discharge or death. We hypothesized that levels of serum galectin-3 upon hospital admission could identify patients at high-risk of progressing to a severe COVID-19 outcome resulting in invasive mechanical ventilation (IMV) and/or death. Additionally, galectin-3 levels were correlated with clinical and inflammatory laboratory markers. COVID-19 patients were diagnosed as either critical (>50% lung damage) or moderate (<50% of lung damage) based on computerized tomography (CT). We found that elevated serum galectin-3 was significantly higher in critical patients compared to moderate ones and was found to be an independent predictor of severe outcome regardless of the percentage of lung involvement. Results from this study indicate that galectin-3 may be a useful prognostic biomarker in COVID-19 patients to provide early identification of patients at high risk of severe illness and to provide guidance on resource allocation. Further studies are warranted to understand the potential pathophysiological role of galectin-3 in COVID-19 disease progression and the development of targeted therapies. presumably reflecting a greater inflammatory state due to more severe lung damage. The total All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. To explore the possible role of galectin-3 as a biomarker of severity, circulating levels were measured in sera from COVID-19 patients using a commercial enzyme-linked immunosorbent assay (ELISA). We found that COVID-19 patients upon hospital admission had significantly elevated circulating levels of galectin-3 when compared to age-matched pre-pandemic healthy subjects ( Figure 1a) . Critical patients had significantly higher levels of galectin-predicting severe outcomes in the moderate group compared to CRP (AUC=0.95, p<0.0001, and AUC=0.87, p<0.01, respectively) (Figure 2f ). Given that elevated galectin-3 levels were found in patients who progressed to a severe outcome, and considering its participation in the inflammatory response, correlations with inflammatory parameters previously studied in COVID-19 using the spearman correlation coefficient, in accordance with the non-normal distribution of the data were carried out. We To assess the discriminative power of galectin-3 as a predictor of severe outcome, ROC curves were plotted. Galectin-3 discriminates well between critical and moderate patients with an AUC We performed a forward-stepwise logistic regression analysis to identify independent demographic and laboratory parameters that strongly correlated with a severe outcome, and thus with disease progression (i.e., IMV and/or death). A smoothing spline of galectin-3 showed a non-linear relationship with severe outcome; therefore, we used the Youden's J statistic to determine the ideal binary cut-point of galectin-3 for classifying severe outcomes Table 2 ). Of note, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 9, 2021. ; https://doi.org/10.1101/2021.02.07.21251281 doi: medRxiv preprint CRP and albumin were entered as continuous variables according to their smoothing splines which showed linear relationships with severe outcome (Supplementary figure 2b -c) We also explored the potential for using binary cut-points of CRP and albumin to classify severe outcomes. CRP had an AUC of 0.76 (95% CI 0.68 -0.85, p<0.0001) at a cut-point of 14 (Figure 4b -c) . We then assessed if the combination of galectin-3, CRP and albumin could better classify severe outcomes in COVID-19 patients than either marker on its own. To determine this, the predicted probabilities for this combination of values were computed and plotted in a ROC curve (Figure 4d) . The AUC showed an enhanced ability to classify severe outcomes compared to each value independently 0.84 (95% CI 0.77 -0.91, p<0.0001). In this prospective cohort of COVID-19 patients, we assessed the classification performance of circulating galectin-3 levels obtained upon hospitalization on the development of a severe outcome, defined as requirement of IMV and/or death. We hypothesized that this molecule could be associated with symptom severity due to its known involvement in the exacerbated inflammatory response, a feature that has been exhibited in COVID-19 patients (3). The hyperinflammatory state in COVID-19 patients and its relationship with galectin-3 was observed in this study, as higher levels of this lectin upon admission were found in critical patients with lung affection greater than 50%. Our results indicate that galectin-3 levels above 30 .59 ng/mL discriminate between patients with critical or moderate disease with a high specificity. ARDS is characterized by a diffuse alveolar damage in the lung, caused by the severe inflammatory process (25) . The high levels of galectin-3 found in these patients might be All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 9, 2021. an indication of the possible role of galectin-3 in the pathophysiology of ARDS and might be a reflex of the excessive inflammatory response associated with ARDS in these patients. Evidence in the literature has implicated the cytokine release syndrome as the main factor responsible for the high mortality observed in COVID-19 patients (26) . Specifically, IL-6 and TNF-α have been found to be independent predictors of severity and poor outcome (3). Galectin-3 is a leading orchestrator of the inflammatory response syndrome by activating and triggering the release of inflammatory cytokines. Our observations indicate that higher galectin-3 levels are found in those patients with a severe outcome. Furthermore, we found that galectin-3 possesses power as an independent predictor of severe outcome when adjusting for age, gender, comorbidities and other inflammatory parameters. ARDS in COVID-19 leads to more severe outcomes than ARDS due to other causes (27) . With a general mortality of 26%-61.5% in those admitted to the intensive care unit, and significantly higher in those requiring IMV (65.7% to 94%) (27) . Our results indicate that values greater than 30.99 ng/mL have a high sensitivity and specificity to predict an adverse clinical course with the possibility of requiring IMV and/or death. Galectin-3 was not only able to classify a severe outcome in critical patients, but, more importantly, was able to identify severe outcomes in moderate patients (AUC= 0.95). While IMV is intended to minimize the progression of lung injury (28) , it has been also demonstrated to induce or aggravate lung damage and in the long-run may contribute to lung fibrosis (4, 29) . Chronic pulmonary fibrosis has been observed in recovered COVID-19 patients (10, 24) . Galectin-3 is known to play a role in the pathogenesis of pulmonary fibrosis, and clinical trials testing galectin-3 inhibitors are currently underway for the treatment of idiopathic pulmonary fibrosis (30) . Galectin-3 could provide an important biomarker for severe COVID-19 with potential for involvement in the direct pathophysiological process of the underlying disease. To better understand the relationship between galectin-3 and the inflammatory response after SARS-CoV-2 infection, we explored its association with CRP. CRP, an acute inflammatory biomarker with ability to predict mortality in COVID-19 (31, 32) , was identified as an independent predictor of severe outcome in our cohort and had a positive correlation with galectin-3. This novel association between galectin-3 and CRP has not been reported in viral infection, much less in COVID-19 but it suggests the utility of this molecule in detecting the inflammatory state of patients upon hospital arrival. As both CRP and galectin-3 were identified as independent predictors, we sought to identify which one would perform better according to its All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 9, 2021. ; https://doi.org/10.1101/2021.02.07.21251281 doi: medRxiv preprint association with patient outcome. The non-linear relationship of galectin-3, observed in a smoothing spline, demonstrated that higher levels of this lectin were a common characteristic of patients at high-risk of progressing to a severe COVID-19 outcome. We consider that inflammatory markers such as CRP which tend to show a linear relationship with outcome may not be suitable as efficient biomarkers given their inconsistency, as different cut-off values have been reported; therefore galectin-3 may present an advantage over this commonly measured laboratory parameter, as it showed more accuracy when identifying patients prone to disease progression. Furthermore, although a slope could be interpreted by healthcare providers for continuous predictors, we also appreciated the simplicity of using a binary cut-point of galectin-3 level to classify patients as low or high risk for severe outcomes. Part of the relevance of this molecule in COVID-19 may be also explained given its interaction with neutrophils, a crucial immune cell whose recruitment is essential in the innate immune response against invading pathogens (e.g., SARS-CoV-2). Neutrophilia is also believed to be a key aspect in the cytokine release that has been studied in severe patients (33) which in this cohort was positively correlated with galectin-3, consequently supporting its role in the acute pro-inflammatory response. Moreover, a previous report has shown that galectin-3 is an adhesion molecule that mediates neutrophil adhesion to endothelial cells during Streptococcus pneumoniae infection, confirming its association with lung inflammation as it is actively released after infection (34) . In accordance with earlier studies (35) , we also identified hypoalbuminemia as a common characteristic among critically ill patients and support the correlation between albumin and the systemic inflammation in COVID-19 patients, as a negative correlation was found with galectin-3, which is a known contributor to the release of pro-inflammatory cytokines (12) . Albumin is an important biomarker that reflects the inflammatory state, as its production is decreased due to higher levels of IL-6 (36). Observations carried out by Huang et al. in a large cohort of COVID-19 patients identified the decrease in albumin levels as a significant indicator of progression to a critical stage and death. They associated this pathologic finding with a reduced capacity of synthesis by hepatocytes as mild hepatic injury was evident (37) . Another aspect relevant to consider is that capillary leakage into the interstitial space increases in severe illness such as sepsis, leading to the sequestration of albumin (38) . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 9, 2021. ; https://doi.org/10.1101/2021.02.07.21251281 doi: medRxiv preprint As galectin-3 was found to reflect the hyperinflammatory state of patients, its predictive ability together with CRP and albumin was tested. Results revealed that when used jointly, severe outcomes can be more accurately classified upon hospital admission (AUC=0.84), thus providing clinicians more resources to efficiently identify patients with higher odds of adverse progression. Given that galectin-3 is highly correlated with the severity of the disease, as shown when patients were first classified based of CT findings, we propose that galectin-3 be included in the initial screening of COVID-19 patients, together with CRP and albumin. The assessment of this panel upon admission will help identify patients at high-risk of disease progression as galectin-3 was found to be associated with the patients' clinical state. Therapies that decrease inflammatory response would be expected to reduce galectin-3 levels during the clinical course of the patient and influence outcomes. Further studies are needed to assess whether galectin-3 can provide a useful biomarker to evaluate therapeutic interventions. In this study, we have offered evidence on the prognostic use of galectin-3 in SARS-CoV-2 infected patients which may extend to other critical diseases and propose its combined use with other inflammatory markers to guide the clinical rationale when assessing a hospitalized patient's risk. Inhibitors of galectin-3 have been shown to reduce the levels of both IL-6 and TNF-α in vitro and have shown anti-inflammatory effects in vivo (39) . Based on the data presented here, we also propose galectin-3 as a feasible pharmacological target to minimize the hyperinflammatory phase and the subsequent lung fibrosis in COVID-19 patients. There are some limitations to our study. First, since this is a single-center experience, data from different populations and a multicenter analysis will be needed for validation. Second, due to the small sample size, further clinical studies with larger sample sizes are required to confirm these findings before galectin-3 can definitively be recommended as a standard biomarker in the hospital setting. Despite these limitations, this study demonstrates in a prospective cohort of COVID-19 patients at one of the largest health institutes in Mexico that measurement of galectin-3 levels upon hospital admission could be helpful in predicting disease severity. Finally, the combined use of galectin-3, CRP and albumin showed strong predictive ability, and thus could aid to efficiently allocate medical resources before patients develop an adverse outcome. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 9, 2021. Patients who required IMV and/or died during hospitalization were categorized as having a severe outcome. Patients who recovered and were discharged without requiring IMV were categorized as having a non-severe outcome. Clinical and laboratory data were extracted from the electronic medical records including: Demographics (age, gender, comorbidities), clinical (days of hospital stay), radiological (chest CT findings), laboratory and patient outcome data (need for IMV and/or death). Laboratory data included arterial blood gas, complete blood count, triglycerides, albumin, lactate dehydrogenase, liver enzymes, coagulation tests (D-dimer, INR) and inflammation-related parameters (CRP and ferritin). Blood samples were collected upon hospital admission from all 156 patients. Samples were centrifuged at 3,000 rpm for 10 min, and serum was aliquoted and stored at -70°C until further analysis. Galectin-3 was measured in the serum samples using a commercial ELISA Kit (Invitrogen, #BMS 279-4, Carlsbad, CA, USA), according to the manufacturing instructions. All All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 9, 2021. ; https://doi.org/10.1101/2021.02.07.21251281 doi: medRxiv preprint samples were evaluated in duplicate. The inter-assay coefficient of variation was 8.52% and the intra-assay 5.34%. Data are expressed as frequencies for categorical variables and as mean with standard deviation (SD) or median with interquartile range (IQR) for continuous variables according to The authors declare no conflicts of interest that pertain to this work All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 9, 2021. ; This work was supported by the grant #312285 from Consejo Nacional de Ciencia y Tecnología Fig. 1: Galectin-3 serum levels in COVID-19 patients. a, Galectin-3 circulating levels upon hospital admission of COVID-19 patients (n=156) and age-matched healthy pre-pandemic controls (n=10). b, Galectin-3 is associated with COVID-19 severity, critical patients (n=94) presented significantly higher levels than moderate patients (n=62). c, Severe outcomes in COVID-19 patients were associated with elevated levels of galectin-3. Data in a and c are shown as median with IQR, data in b as mean ± SD. ***p < 0.001, ****p < 0.0001; two-tailed Mann-Whitney U test or two-tailed t-test. Samples were assessed in duplicate in ELISA assays. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 9, 2021. ; https://doi.org/10.1101/2021.02.07.21251281 doi: medRxiv preprint Fig. 2: Galectin-3 and CRP as predictors of severe outcome in moderate and critical COVID-19 patients. a, significantly higher galectin-3 levels associate with severe outcome in both critical and moderate groups b,c, Receiver-operating characteristic (ROC) curves show that galectin-3 has a significant predictive power for severe outcome in critical (b) and moderate patients (c). d, Similarly, C-reactive protein (CRP) levels are elevated in critical and moderate patients with severe outcome. e, f, Predictive power is also found with CRP when ROC curves for severe outcome are plotted in both groups. Data in a and d are shown as median with IQR. **p < 0.01, ****p < 0.0001; two-tailed Mann-Whitney U test. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 9, 2021. ; https://doi.org/10.1101/2021.02.07.21251281 doi: medRxiv preprint Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges An inflammatory cytokine signature predicts COVID-19 severity and survival Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 A Systematic Review of Cases of Acute Respiratory Distress Syndrome in the Coronavirus Disease Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis Pulmonary fibrosis secondary to COVID-19: a call to arms? Structure and function of a large family of animal lectins Galectin 3 induces a distinctive pattern of cytokine and chemokine production in rheumatoid synovial fibroblasts via selective signaling pathways Galectin-3 promotes adhesion of human neutrophils to laminin Human galectin-3 is a novel chemoattractant for monocytes and macrophages Epsilon BP, a beta-galactoside-binding animal lectin, recognizes IgE receptor (Fc epsilon RI) and activates mast cells The regulation of inflammation by galectin-3 Galectin-3 Enhances Avian H5N1 Influenza A Virus-Induced Pulmonary Inflammation by Promoting NLRP3 Inflammasome Activation The fibrosis marker galectin-3 and outcome in the general population Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3 Role of galectin-3 in human pulmonary fibrosis The Predictive Value of Plasma Galectin-3 for Ards Severity and Clinical Outcome Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy Acute respiratory distress syndrome: pathophysiology and therapeutic options Cytokine release syndrome in severe COVID-19 Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Early improvements in pulmonary function after severe COVID-19 requiring mechanical ventilation Mechanical ventilation-associated lung fibrosis in acute respiratory distress syndrome: a significant contributor to poor outcome Targetinhibition of Galectin-3 by Inhaled TD139 in Patients with Idiopathic Pulmonary Fibrosis Prognostic value of C-reactive protein in patients with COVID-19 C-reactive protein levels in the early stage of COVID-19 Excessive Neutrophils and Neutrophil Extracellular Traps in COVID-19 Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity IL-6 in inflammation, immunity, and disease Decreased serum albumin level indicates poor prognosis of COVID-19 patients: hepatic injury analysis from 2,623 hospitalized cases The role of albumin in critical illness Gal-3 is a potential biomarker for spinal cord injury and Gal-3 deficiency attenuates neuroinflammation through ROS/TXNIP/NLRP3 signaling pathway BMI= Body mass index, IMV= Invasive mechanical ventilation, INR= International normalized ratio, CRP= C-reactive protein, NLR= Neutrophil to lymphocyte ratio, MAP= Mean arterial pressure Galectin-3 associates with CT findings upon hospital admission as it shows power discriminating between critical patients (>50% of lung affection) and moderate patients (<50% of lung affection). Values for AUC, sensitivity (SE), specificity (SP), likelihood ratio (LR) and cutpoint values are shown, with 95% CIs in parentheses.